Meet the Pentara Team at Booth #100
Come to chat with us to see how we’re optimizing clinical trial designs and making complex clinical data easier to understand!
Suzanne Hendrix, Ph.D.
Continued Or Time-limited Treatment Benefits Of Anti-amyloid Monoclonal Antibodies In Early Alzheimer’s Disease
Quantifying The Improved Treatment Effect Of Lecanemab And Donanemab In Minority Populations With Comorbidities
Samuel Dickson, Ph.D.
Racial-specific biomarker cutoff is needed to increase inclusion in Alzheimer’s clinical trials
Garrett Duncan, M.S.
Quantifying The Synergistic Treatment Effect Of Lecanemab And Donanemab In Comorbid Populations
Caleb Dayley, M.S.
Optimizing Pre-Symptomatic Alzheimer’s Trials: A Power Comparison of Continuous Endpoints vs. Time-to-Event Analysis
Patrick O'Keefe, Ph.D.
GSTs in the Framework of Structural Equation Models: Type I error and power
Caleb Dayley, M.S.
Why Placebo Progression Should Be the Gold Standard for Endpoint Validation in Clinical Trials for Progressive Diseases
John Whetten, M.S.
Estimating Time Savings for Individual Participants in Clinical Trials for Progressive Diseases
Daniel Smith, M.S.
Comparing Parametric and Non-Parametric Time Saving Estimates in Clinical Trials